Actively Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-12-19
36
Participants Needed
5
Research Sites
172 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
N
Nanjing Legend Biotech Co.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.
CONDITIONS
Official Title
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation with signed informed consent and good compliance
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Presence of measurable lesions
- Diagnosis of relapsed and/or refractory multiple myeloma
- Life expectancy of 3 months or more
- Clinical laboratory values meeting screening requirements
- Adequate organ function
You will not qualify if you...
- Prior antitumor therapy without sufficient washout period
- Previous treatment targeting GPRC5D
- Positive test for hepatitis B surface antigen, hepatitis B virus DNA, hepatitis C antibody, hepatitis C virus RNA, or HIV antibody
- History of severe allergic or hypersensitivity reactions to study drug excipients or related substances
- Any condition considered by the investigator to make participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Henan Cancer Hospital
Zhengzhou, Henan, China
Not Yet Recruiting
2
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Actively Recruiting
3
The Affiliated Hospital of XUZHOU Medical University
Xuzhou, Jiangsu, China
Not Yet Recruiting
4
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Not Yet Recruiting
5
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Not Yet Recruiting
Research Team
L
Lijuan Chen
CONTACT
X
Xuxing Shen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here